Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha.

doi:10.1016/j.bbmt.2016.03.015

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation - 1 Jun 2016

Kurosawa Saiko, Yamaguchi Hiroki, Yamaguchi Takuhiro, Fukunaga Keiko, Yui Shunsuke, Wakita Satoshi, Kanamori Heiwa, Usuki Kensuke, Uoshima Nobuhiko, Yanada Masamitsu, Shono Katsuhiro, Ueki Toshimitsu, Mizuno Ishikazu, Yano Shingo, Takeuchi Jin, Kanda Junya, Okamura Hiroshi, Inamoto Yoshihiro, Inokuchi Koiti, Fukuda Takahiro

Abstract excerpt

We performed a decision analysis comparing allogeneic hematopoietic cell transplantation (allo-HCT) versus chemotherapy in first complete remission for patients with cytogenetically intermediate-risk acute myeloid leukemia, depending on the presence or absence of FLT3-internal tandem duplication (ITD), nucleophosmin (NPM1), and CCAAT/enhancer binding protein alpha (CEBPA) mutations. Adjusted means of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CCAAT-Enhancer-Binding Protein-alpha

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytogenetic Analysis

Share to Decision Support Techniques

Share to fms-Like Tyrosine Kinase 3

Share to Markov Chains

Share to Nucleophosmin

Share to Remission Induction

Share to Transplantation, Homologous

Source

Open in PubMed

Identifiers

PMID: 27040395
DOI: 10.1016/j.bbmt.2016.03.015

Genes

FLT3
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha.PMID 27040395Read ↗

A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remissionSemantic proximity Read ↗

Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.Semantic proximity Read ↗

Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials.Semantic proximity Read ↗

Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.Semantic proximity Read ↗

Comparative Efficacy of Intensive Frontline Regimens in FLT3-Mutated AML: A Bayesian Network Meta-Analysis of Randomized TrialsSemantic proximity Read ↗

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.Semantic proximity Read ↗

The role of HLA-matched unrelated transplantation in adult patients with Ph chromosome-negative ALL in first remission. A decision analysis.Semantic proximity Read ↗

Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia.Semantic proximity Read ↗

Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.